GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Optimind Pharma Corp (XCNQ:OMND) » Definitions » Inventories, Raw Materials & Components

Optimind Pharma (XCNQ:OMND) Inventories, Raw Materials & Components : C$0.00 Mil (As of Aug. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Optimind Pharma Inventories, Raw Materials & Components?

Optimind Pharma's inventories, raw materials & components for the quarter that ended in Aug. 2024 was C$0.00 Mil.


Optimind Pharma Inventories, Raw Materials & Components Historical Data

The historical data trend for Optimind Pharma's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Optimind Pharma Inventories, Raw Materials & Components Chart

Optimind Pharma Annual Data
Trend Feb22 Feb23 Feb24
Inventories, Raw Materials & Components
- - -

Optimind Pharma Quarterly Data
Jun21 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Optimind Pharma Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Optimind Pharma Business Description

Industry
Traded in Other Exchanges
N/A
Address
77 King Street West, Suite 3000, TD Centre, North Tower, PO Box 95, Toronto, ON, CAN, M5K 1G8
Optimind Pharma Corp is an emerging provider of psychedelic therapies for the masses. It helps people suffering from PTSD, Anxiety, Depression, and other mental illnesses and disabilities by providing ketamine-assisted-treatment and other psychedelic-enhanced-psychotherapy modalities. It is also partnered with developers of psilocybin-associated treatments and products to further expand its treatment and program offerings.

Optimind Pharma Headlines

No Headlines